Premium
Alternating Appearance of IgD and IgG Myeloma Protein during Treatment
Author(s) -
Oxelius ViviAnne
Publication year - 1971
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1971.tb00896.x
Subject(s) - bence jones protein , immunoglobulin d , kappa , antibody , lambda , immunoglobulin light chain , immunology , microbiology and biotechnology , medicine , chemistry , biology , mathematics , physics , b cell , optics , geometry
A patient with widespread IgD‐myelomatosis is described. The serum electrophoretic pattern exhibited at discovery of the disease two M‐components: one of IgD‐lambda type migrating in the γ 1 ‐region and one of Bence Jones protein lambda type in the β 1 ‐region. A Bence Jones protein of lambda type was also detected in the urine. During treatment with cyclophosphamide the IgD‐lambda‐ and serum Bence Jones lambda‐proteins disappeared and the urine Bence Jones lambda protein decreased. After 8 months' treatment another M‐component was recognized in the slowest γ‐region. This M‐component was IgG, subclass IgG1 of kappa type. No signs of the IgGl component were seen when the first serum samples were retested with a specific antiserum raised against the IgG‐kappa component. In the following samples also the IgG‐kappa component decreased but traces were still demonstrable in all late samples. The patient improved during treatment. In the last obtained serum sample a reactivation of the IgD‐lambda‐ and Bence Jones lambda‐clones was seen.